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erence for DBS over CDLCI (OR 8.02, 95% CI6.17-10.38). Avoiding deterioration in
movement was also important in determining treatment choice (OR0.67;
95%CI0.57-0.79) as was avoiding limitations on daily activities; (OR0.69;
95%CI0.54-0.88). CONCLUSIONS: CPD patients were able to engage in this quite
complex task to indicate their views regarding treatments. Participants had a pref-
erence for DBS surgery type. Maintaining movement and daily activities were also
important attributes. As the surgery attribute was a composite of both surgical
procedure and daily maintenance, further study is needed to identify which of
these aspects is the strongest predictor of patient preferences. Finally, a larger
study is needed to understand the importance of attributes for all the treatment
alternatives that can be offered to CPD patients
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OBJECTIVES: To develop and subsequently evaluate content validity of questions
assessing patient preference between two dry powder inhaler (DPI) devices (the
Handihaler and the Novel DPI) for the treatment of chronic obstructive pulmonary
disease (COPD), based on ease of use. METHODS: Initial COPD Device Preference
Questionnaire (CDPQ) items were designed to assess inhaler device preference
based on aspects of ease of use identified as important by COPD patients and
physicians during previous research. Two iterative rounds of semistructured, in-
depth interviews were conducted in adult patients currently receiving COPD med-
ication via the Handihaler. Initially, patients were asked to describe the actuation
of the Handihaler. Next, the features and steps required to operate the Novel DPI
were described, and participants were asked to demonstrate using an empty de-
vice. Cognitive debriefing of the CDPQ was then conducted. Patients completed and
evaluated five items, each phrased two different ways (beginning with “which. . .”
or “thinking. . .”). Round 1 interviews (n 8) gathered feedback on preferred phras-
ing and modifications required to improve the CDPQ. Round 2 interviews (n  8)
assessed modifications and gathered additional input to confirm content validity.
All interviews were recorded and transcribed for analysis. RESULTS: Round 1 in-
terviews resulted in addition of instruction detail, modification of questions based
on a clear preference for the “which” phrasing, and removal of two items (i.e.,
understanding how to use the device and number of steps involved in preparing
the device) deemed duplicative. Round 2 interviews did not result in additional
changes. Participants found instructions, items, and response wording easy to
understand and complete. An item-tracking grid was constructed to summarize
item changes and their rationales. CONCLUSIONS: Participant feedback indicates
that the concepts of greatest importance in determining COPD inhaler device pref-
erence related to ease of use were reflected in the final CDPQ items.
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OBJECTIVES: Sleep issues are relevant to women across their whole lifespan and
this is especially true during the climacteric period. Previous studies have demon-
strated that insomnia influences quality of life (QOL) across various different do-
mains. However, the different characteristics of the insomnia that influences the
QOL remain unclear. Our study was designed to investigate which type of insomnia
influences the health-related quality of life amongst women. METHODS: A total of
1098 women age between 40-60 years seeking medical advice were drawn from two
hospital, with a further 314 healthy referents of the same age, range and gender,
with no history of hormone replacement therapy and living in the same munici-
pality, also being recruited from a national health survey sample for comparison.
Each one was asked to fill out a brief questionnaire, the Taiwan version of the
World Health Organization Quality of life (WHOQOL-BREF), which assesses quality
of life based on 26 items in four domains (physical, psychological, social and envi-
ronmental). In addition, the Pittsburgh sleep quality index (PSQI) was used to eval-
uate the sleep quality and insomnia pattern of the subjects. Multiple regression
analyses were conducted to control variables such as age, marital status, religion,
educational attainment and menopausal status. RESULTS: The mean total score of
the PSQI was 7.5  3.8 with a range from 0-20. In the 1098 participants, 65.3%
(n717) were confirmed to be poor sleepers, and 34.7% (n381) were good sleepers.
After controlling for the demographic factors, it was found that subjective poor
sleep quality and daytime dysfunction were the major determinants of the scores
in the different domains. CONCLUSIONS: A high incidence of poor sleep quality
exists among climacteric women in the urban area of Taiwan and subjective poor
sleep quality and poor daytime function should be taken into consideration in the
management of climacteric women seeking medical advice.
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OBJECTIVES: The objective of this study was to validate clinician and patient mea-
sures of satisfaction and preference for pharmacological stress agents (PSAs) used
in Single Photon Emission Computed Tomography (SPECT) Myocardial perfusion
imaging (MPI) procedures using classical and novel psychometric methods.
METHODS: Psychometric validation of the Clinician Satisfaction and Preference
Questionnaire (CSPQ) and the Patient Satisfaction and Preference Questionnaire
(PSPQ) was conducted in a sample of 90 patients and 15 clinicians. Due to the small
sample size, a Bayesian Item Response Theory was utilized to validate the initial
parameter estimates. Specifically, item difficulty was evaluated using patient char-
acteristics as the known prior distributions. RESULTS: The CSPQ demonstrated
strong internal consistency (alpha0.99) and moderate point-biserial correlations
between PSA satisfaction scores and agent preference (range 0.63-0.65). The PSPQ
‘preparation’ and ‘reaction to agent’ scales demonstrated strong internal consis-
tency (alpha0.90 and 0.87 respectively). Test-retest reliability was acceptable for
all PSPQ scales (ICC range0.73 to 0.86). Concurrent validity with the Treatment
Satisfaction Questionnaire for Medication (TSQM) indicate low to moderate corre-
lations between the Effectiveness, Convenience and Global Satisfaction scales of
the TSQM with the PSPQ Satisfaction with Administration, Satisfaction with Effects
and Overall Satisfaction items (range 0.46 to 0.78). The results of the Bayesian
analysis indicated consistency between the two approaches. Specifically, item dif-
ficulty was invariant across the various patient demographics.CONCLUSIONS:The
CSPQ and PSPQ were developed and validated using rigorous, gold standard meth-
odology. The resulting instruments sufficiently represents meaningful domains
demonstrate strong internal consistency, good test-retest reliability, and predic-
tive validity associated with clinician and patient measures of satisfaction and
preference for pharmacological stress agents (PSAs) used in Single Photon Emis-
sion Computed Tomography (SPECT) Myocardial perfusion imaging (MPI) proce-
dures. The variance in the item parameters were fully explained by the summary
demographic information on the patients and physicians as supported by the
Bayesian analysis.
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OBJECTIVES: In CT imaging, as preparation procedure for contrast media (Iopro-
mide), the use of prefilled cartridge (PFC) is simpler compared to glass bottle (GB).
There are several benefits such as infection control and time saving. This study
examined the benefits of contrast media with PFC compared to GB.METHODS: The
benefits are defined as the cost savings which can occur when used in various
situations. A decision analytic model was created to evaluate the effectiveness
according to the type. The use of each type could finally lead to local infection and
blood stream infection (BSI). We estimated the benefits using the probability of
infection from decision model and treatment costs from insurance claims data. To
estimate the benefits of time saving, we measured the preparation time repeatedly
in general hospitals. Assuming that the reduced time was replaced with CT scan in
new patients, we estimated the time saving benefits by multiplying the result to the
cost of CT scan. RESULTS: The material cost of GB was $74.8 which is higher than
$72.9 of PFC. In contrast, in case of GB, the probability of contamination, local
infection and BSI were 3.3%, 1.25%, 0.060% respectively, which were higher than
PFC (0%, 1.22%, 0.058%). The benefit in reduction of infection was estimated at $0.20
per case in PFC. The reduced time from using PFC has an average of 51.9 seconds
based on 113 observations from 3 general hospitals. The time saving benefit was
estimated at $7.16 per case. Therefore, the total benefit was estimated at $7.36.
CONCLUSIONS:This study showed that PFC dominated GB (lower costs, and higher
benefits). This was driven by lower material cost, lower infection risk and admin-
istration time for PFC compared to GB. Findings of this study suggest that the use of
PFC contrast media is an efficient utilization of resources in Korea.
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DEVICES IN THE GERMAN SYSTEM OF DIAGNOSIS RELATED GROUPS (G-DRG):
THE CASE OF DRUG-ELUTING STENTS IN PATIENTS WITH ACUTE
MYOCARDIAL INFARCTION
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OBJECTIVES: The aim of the study was to measure the effect of supplementary fees
on the use of drug-eluting stents (DES) in AMI patients instead of conventional
bare-metal stents (BMS). German DRG fees do not distinguish between different
types of coronary stents. To compensate hospitals for higher costs of DES, supple-
mentary payments could be negotiated between the hospital and the sickness
funds.METHODS:Administrative data of one of the largest German sickness funds
was used to identify the determinants of DES use in AMI patients. The dataset
contained information on demographic characteristics and co-morbidities on pa-
tient level. Information on hospital and regional level including the supplementary
fee for the use of DES was merged. 9.453 patients with an admission due to an AMI
and the implantation of a BMS or DES between 2004 through to 2006 were included
in the analysis. For analyzing the data, a logistic multilevel regression approach
was used; the dependent variable was binary, taking the value of 1 if a DES was
implanted and 0 if a BMS was implanted. In the regression, a comprehensive set of
covariates on patient level as well as variables on hospital and regional level were
included. To test robustness of the estimation, several models were estimated.
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RESULTS: A substantial share of the variance (around 20%) was related to the
hospital level. Preliminary results suggest that supplementary fees had a border-
line significant positive impact on DES use. Further hospital characteristics also
had a significant impact on the use of DES (p0.05), as well as area characteristics.
CONCLUSIONS: Although there seems to be a small influence of supplementary
fees on the use of DES, further hospitals’ and area characteristics might be of higher
importance than reimbursement incentives. Attributing the diffusion of technolo-
gies to financial incentives only would fall too short.
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OBJECTIVES: Systematic analysis of the available studies of the clinical effective-
ness and safety of negative pressure therapy, as compared with traditional courses
of treatment, in complex foot wounds in diabetic patients. METHODS: A biblio-
graphical search was performed in the following databases: Embase.com, Medline
and Cochrane Library, covering from 2000 until the present. The following descrip-
tors and key words were used: diabetic foot, negative-pressure wound, vacuum-
assisted closure and diabetic ulcers. The Jaddad criteria were used to determine the
quality of the clinical trials. The studies selected were randomized clinical trials
that featured patients older tan 18 years, with complex ulcers, postoperative
wounds, or wounds resulting from the amputation of the foot, with a control group
comparing negative pressure therapy with conventional therapies (saline solution,
alginates or hydrophilic substances. The treatments were applied every 48 hours. A
total of 12 studies, of which only 7 were pertinent, were selected. Two independent
reviewers extracted the information and determined the methodological quality of
the selected studies. RESULTS: Of the 7 studies selected (539 patients), 5 involved
patients with postoperative wounds and 2 used the same group of patients. One of
the two studies involving ulcers of the foot was limited by its simple size (N10).
The methodological quality of the studies is moderate-low. CONCLUSIONS: The
evidence supports the effectiveness and security of negative pressure wound ther-
apy in complex foot ulcers in diabetic patients. Given that it is unlikely that further
research will change this positive appraisal (despite the moderate-low quality of
the studies analyzed, its cost profile and the absence of adverse effects) it is possi-
ble to make a strong recommendation in favor of the therapy.
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OBJECTIVES: Based on clinical trial evidence, remote follow-up (FU) has been rec-
ommended for replacing in office visits routinely scheduled to monitor device
functionality and health status of patients with CIED. No data exist on the actual
demand for such visits. To estimate the total number of calendar based in-office FU
visits in Germany and the UK (UK) by 2015. METHODS: Official national sales data
for implantable pacemakers (PM), cardioverter defibrillators (ICD) and cardiac re-
synchronisation therapy (CRT) devices were combined with published replace-
ment rates and estimates for patient mortality and device longevity. Following
HRS/EHRA guidelines on FU frequency, demand for FU consultations until 2015 was
modelled. RESULTS: For 2010, the model estimates about 677’800 prevalent pa-
tients with a CIED in Germany and 225,000 in the UK. The growth in CIED patients
recently seen in the UK is expected to slow down but to continue to be higher than
in Germany (8.3% per annum until 2015 versus 4.8%). Assuming two annual visits
for PM patients and four visits for ICD and CRT patients, the total number of routine
FU visits is estimated to increase from 1.66 mio in Germany (2010) to 2.23 mio
(2015). For the UK, service numbers will increase from 538,000 (2010) to 836,000
(2015). These estimates do not include unscheduled FU visits. CONCLUSIONS: Reg-
ular FU services for CIEDs are mandatory to ensure device functionality and mon-
itor disease status. Increasing patient volumes will push demand for these ser-
vices, placing a potentially unmanageable burden on cardiology service providers,
payers and patients, unless infrastructure investments occur. High demand for
services and low actionability of routine visits may result in inappropriate guide-
line adherence with potentially negative impact on patient safety and device lon-
gevity. Clinics need to become aware of this situation and adopt strategies for
handling the expected workload in the future.
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OBJECTIVES: To assess the cost-effectiveness of transcatheter aortic valve implan-
tation (TAVI) versus medical management (MM) for severe aortic stenosis (AS) in
elderly patients with excessive surgical risk. METHODS: A Markov model was de-
veloped of survival, quality-adjusted life-years (QALYs) and medical costs, in el-
derly patients in the UK with severe AS and excessive risk for conventional aortic
valve replacement (cAVR). Incremental cost-effectiveness ratios (ICERs) were esti-
mated as cost per QALY-gained, from the National Health Service (NHS) perspec-
tive, over 3 years. Clinical and utility outcomes over the first year were derived from
published results of a head-to-head randomized controlled trial comparing [trans-
femoral] TAVI and MM. Base-case analyses assumed no additional procedure-re-
lated adverse events after the first year—not including re-hospitalizations due to
cardiovascular events—and constant treatment-specific mortality after the first
month. Costs of procedures, adverse events, re-hospitalizations and long-term
health care utilization were estimated using NHS tariff and reference cost sched-
ules, National Institute of Health and Clinical Excellence reports, peer-reviewed
literature and clinical experts. Outcomes and costs (2010£) were discounted at 3.5% per
annum. RESULTS: Under conservative assumptions, treatment with transfemoral
TAVI is estimated to result in better survival (35% vs. 13% at three years) and more
QALYs (1.17 vs. 0.76) than MM. TAVI is also associated with higher costs of initial
treatment and procedure-related adverse events, partially offset by lower costs of
re-hospitalizations (net costs of £34,500 vs. £23,700). The base-case ICER of £26,100
is sensitive to variation in assumptions about long-term mortality for MM and
long-term cardiovascular events for TAVI but remains below £30,000; the model is
also sensitive to assumptions on long-term care use. CONCLUSIONS: In elderly
patients who are contraindicated for cAVR, TAVI is estimated to result in better
survival and fewer re-hospitalizations over a three-year period compared with MM,
and can be considered cost-effective at 3 years with a base-case ICER of £26,000.
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OBJECTIVES: The objectives of this study were to: 1) evaluate, from a global per-
spective, the decision-making processes, roles of individuals involved, and physi-
cians’ and administrators’ beliefs about future decision making for the adoption of
cardiovascular devices and medical technologies; and 2) determine which clinical
and health economic factors decision makers consider the most influential and
what types of data they use when making decisions. METHODS: We surveyed
cardiovascular physicians and hospital administrators in the US, UK, Australia,
France, Germany, and Japan using a web-based questionnaire. Respondents were
asked about their involvement in and opinions on the decision-making process in
their institutions, and the role that clinical and economic data play in influencing
decisions. Chi-squared tests were used to test for statistical differences between
physicians and hospital administrators (all countries combined) and across
countries. RESULTS: The questionnaire was completed by 151 physicians and 154
administrators across the six countries with roughly 25 physicians and 25 hospital
administrators responding from each. Physicians, followed by hospital commit-
tees, were most frequently responsible for making decisions, but respondents be-
lieved influence would shift towards committees in the future. Physicians (78%)
and administrators (81%) believed costs would more heavily influence decisions in
the next 5 years. Approximately half of hospital administrators consulted eco-
nomic data often when making device adoption decisions. Use varied somewhat by
country with most frequent use by both physicians and hospital administrators in
the U.S., U.K., and Australia. CONCLUSIONS: Physicians’ and hospital administra-
tors’ roles in decision making for cardiovascular devices appear to be changing in
many countries, with committees and administrators assuming more important
roles. While clinical data is most influential to the decision process, the impact of
health economic data seems to be growing.
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OBJECTIVES: To collect real-life data from a Swedish setting on treatment patterns
and frequency of urinary tract infection (UTI), amongst patients in presumed need
of chronic, intermittent catheterisation.METHODS:We used the CEBRxA database,
which combines data from a public claims database for the South-West region of
Sweden, comprising around 1.5 million individuals, with national Swedish regis-
ters on drug utilisation and mortality. We identified two sets of patients; Population
I: spinal injury, in addition to neurogenic bladder, and Population II: self-catheteri-
sation training (GB005). A list of antibiotics, known for their frequent use in treating
UTIs was used to evaluate treatment patterns. In addition, a prophylactic treat-
ment for UTI was evaluated (J01AXX05). An antibiotic regime was defined through
considering all dispatches that occurred within 14 days from each other, simulta-
neously (data available from 2005-07-01 until 2009-12-31). RESULTS: We identified
295 and 989 patients for Population I and II, respectively. Both populations con-
sisted primarily of males, while Population I was on average much younger (44 vs.
65 years). For Population I, we observed an average frequency of 2.5 UTI-related anti-
biotic regimes per year. For Population II, an average rate of 1.9 UTIs per year was
observed, while females showed an elevated rate of 2.5. Interestingly, prophylactic use
of antibiotics was widespread in Population I, with usage in 25% of patients, while for
Population II, only 3% of patients had dispatched J01AXX05. An evaluation of the
prescribed dose for Population I prophylaxis users, pointed to an almost continuous
use, at an average 235 DDD per patient and year. CONCLUSIONS: Through studying
UTI-related antibiotic treatment patterns we demonstrated a high disease burden
for UTIs in two, primarily male, populations, in presumed catheterisation need.
The frequent use of prophylactic treatment in the spinal injury population pointed
to an even larger disease burden for these patients.
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